Zimberelimab
Modify Date: 2024-01-10 21:24:34
Zimberelimab structure
|
Common Name | Zimberelimab | ||
|---|---|---|---|---|
| CAS Number | 2259860-24-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZimberelimabZimberelimab is a fully human IgG4 anti-PD-1 monoclonal antibody with high affinity and selectivity. Zimberelimab shows antitumor activities and can be used for various cancers research including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma[1]. |
| Name | Zimberelimab |
|---|
| Description | Zimberelimab is a fully human IgG4 anti-PD-1 monoclonal antibody with high affinity and selectivity. Zimberelimab shows antitumor activities and can be used for various cancers research including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Zimberelimab has an EC50 of 210 pM for human PD-1 but does not bind to related CD28 family receptors, such as ICOS, CD28 and CTLA-4[1]. Zimberelimab binding to cell-expressed human PD-1 inhibits the interaction of the receptor with both human PD-L1 and PD-L2 with IC50s of 580 pM and 670 pM, respectively[1]. Zimberelimab dose-dependently enhances IFN-g production and proliferation by CD4+ T cells, saturating at concentrations below 100 pM[1]. |
| References |
[1]. Markham A. Zimberelimab: First Approval. Drugs. 2021 Nov;81(17):2063-2068. |
| No Any Chemical & Physical Properties |